Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.91 |
| ▸ | NPC1 | O15118 | 7/20 | 0.91 |
| ▸ | CASP1 | P29466 | 1/20 | 0.91 |
| ▸ | TSHR | P16473 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.68 |
| ▸ | HPGD | P15428 | 6/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14155719 | 0.89 | RAB9A (0.83) | RAB9ANPC1CASP1TSHRSMN1; SMN2 | |
| SCHEMBL6238438 | 0.89 | NPC1 (0.78) | RAB9ANPC1CASP1TSHRSMN1; SMN2 | |
| SCHEMBL10943133 | 0.88 | RAB9A (0.86) | RAB9ANPC1CASP1TSHRSMN1; SMN2 | |
| SCHEMBL12411578 | 0.88 | RAB9A (0.69) | RAB9ANPC1CASP1TSHRSMN1; SMN2 | |
| SCHEMBL22441244 | 0.87 | RAB9A (0.69) | RAB9ANPC1CASP1TSHRSMN1; SMN2 | |
| SCHEMBL28735058 | 0.85 | NPC1 (0.68) | RAB9ANPC1CASP1TSHRSMN1; SMN2 | |
| SCHEMBL13412591 | 0.84 | NPC1 (0.71) | RAB9ANPC1CASP1TSHRSMN1; SMN2 | |
| SCHEMBL13227995 | 0.84 | NPC1 (0.71) | RAB9ANPC1CASP1TSHRSMN1; SMN2 | |
| SCHEMBL7564852 | 0.84 | RAB9A (0.79) | RAB9ANPC1CASP1TSHRSMN1; SMN2 | |
| SCHEMBL16374712 | 0.84 | NPC1 (0.69) | RAB9ANPC1CASP1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3931183-B1 | COMPOUNDS WITH FERROPTOSIS INDUCING ACTIVITY AND METHODS OF THEIR USE | FERRO THERAPEUTICS INC (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-114008024-A | Compounds having iron death inducing activity and methods of using the same | 费罗治疗公司 | 2022-02-01 | — | — | CN | disclosed |
| US-20220002280-A1 | COMPOUNDS AND METHODS OF USE | FERRO THERAPEUTICS INC (US) | 2022-01-06 | — | — | US | disclosed |
| US-20220002280-A1 | COMPOUNDS AND METHODS OF USE | FERRO THERAPEUTICS INC (US) | 2022-01-06 | — | — | US | disclosed |
| EP-3931183-A1 | COMPOUNDS WITH FERROPTOSIS INDUCING ACTIVITY AND METHODS OF THEIR USE | Ferro Therapeutics, Inc. (US) | 2022-01-05 | — | — | EP | disclosed |
| US-11040964-B2 | Compounds and methods of use | Ferro Therapeutics, Inc. (US) | 2021-06-22 | — | — | US | disclosed |
| US-11040964-B2 | Compounds and methods of use | Ferro Therapeutics, Inc. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200299283-A1 | COMPOUNDS AND METHODS OF USE | BRIDGEBIO PHARMA, INC. | 2020-09-24 | — | — | US | disclosed |
| US-20200299283-A1 | COMPOUNDS AND METHODS OF USE | BRIDGEBIO PHARMA, INC. | 2020-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002280-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, GPX4, GPX1 | RAB9A 2446/4885NPC1 363/4885CASP1 119/4885 |
| US-20200299283-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, GPX4, GPX1 | RAB9A 2446/4885NPC1 363/4885CASP1 119/4885 |
| US-11040964-B2 | Compounds and methods of use | AIFM2, GPX4, GPX1 | RAB9A 2446/4885NPC1 363/4885CASP1 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.